Antihemophilic factor (recombinant) plasma/albumin-free method for the management and prevention of bleeding episodes in patients with hemophilia A

Biologics: Targets and Therapy

Volumn 3, Issue , 2009, Pages 117-125

  Pipe, Steven W ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Clinical trials; Factor VIII; Hemophilia A; Recombinant proteins

Indexed keywords

EID: 65349195019     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: 10.2147/BTT.S3191     Document Type: Review

References (51)

1. Soucie JM, Evatt B, Jackson D. Occurrence of hemophilia in the United States. The Hemophilia Surveillance System Project Investigators. Am J Hematol. 1998;59:288-294.
2. Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007;357:535-544.
3. Miners AH, Sabin CA, Tolley KH, et al. Assessing health-related quality-of-life in individuals with haemophilia, Haemophilia. 1999;5:378-385.
4. Royal S, Schramm W, Berntorp E, et al. Quality-of-life differences between prophylactic and on-demand factor replacement therapy in European haemophilia patients. Haemophilia. 2002;8:44-50.
5. Shapiro AD, Donfield SM, Lynn HS, et al. Defining the impact of hemophilia: the Academic Achievement in Children with Hemophilia Study. Pediatrics. 2001;108:E105.
6. Globe DR, Curtis RG, Koerper MA. Utilization of care in haemophilia: a resource-based method for cost analysis from the Haemophilia Utilization Group Study (HUGS). Haemophilia. 2004;10(Suppl1):63-70.
7. Soucie JM, Nuss R, Evatt B, et al. Mortality among males with hemophilia: relations with source of medical care. The Hemophilia Surveillance System Project Investigators. Blood. 2000;96:437-442.
8. Pipe S. Consideration in hemophilia therapy selection. Semin Hematol. 2006;43:S23-27.
9. Pipe SW. Recombinant clotting factors. Thromb Haemost. 2008; 99:840-850.
10. Shapiro AD, Korth-Bradley J, Poon MC. Use of pharmacokinetics in the coagulation factor treatment of patients with haemophilia. Haemophilia. 2005;11:571-582.
11. Berntorp E, Boulyjenkov V, Brettler D, et al. Modern treatment of haemophilia. Bull World Health Organ. 1995;73:691-701.
12. Nilsson IM, Berntorp E, Lofqvist T, et al. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med. 1992;232:25-32.
13. Shapiro AD. Anti-hemophilic factor (recombinant), plasma/albuminfree method (octocog-alpha; ADVATE) in the management of hemophilia A. Vasc Health Risk Manag. 2007;3:555-565.
14. Panicker J, Warrier I, Thomas R, et al. The overall effectiveness of prophylaxis in severe haemophilia. Haemophilia. 2003;9:272-278.
15. Shapiro AD. A global view on prophylaxis: possibilities and consequences. Haemophilia. 2003;9 Suppl 1:10-17; discussion 18.
16. Gouw SC, van der Bom JG, Marijke van den Berg H. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood. 2007;109:4648-4654.
17. Molho P, Rolland N, Lebrun T, et al. Epidemiological survey of the orthopaedic status of severe haemophilia A and B patients in France. The French Study Group. secretariat. haemophiles@cch. ap-hop-paris. fr. Haemophilia. 2000;6:23-32.
18. Pneumocystis carinii pneumonia among persons with hemophilia A. MMWR. 1982;31:365-367.
19. Human immunodeficiency virus infection in the United States: a review of current knowledge. MMWR. 1987;36 Suppl 6:1-48.
20. Committee to Study HIV Transmission Through Blood and Blood Products, Institute of Medicine. HIV and the Blood Supply: An Analysis for Crisis Decisionmaking, National Academy Press, Washington, DC; 1995.
21. Keshavjee S, Weiser S, Kleinman A. Medicine betrayed: hemophilia patients and HIV in the US. Soc Sci Med. 2001;53:1081-1094.
22. Chorba TL, Holman RC, Clarke MJ, et al. Effects of HIV infection on age and cause of death for persons with hemophilia A in the United States. Am J Hematol. 2001;66:229-240.
23. Soucie JM, Richardson LC, Evatt BL, et al. Risk factors for infection with HBV and HCV in a largecohort of hemophiliac males. Transfusion. 2001;41:338-343.
24. National Hemophilia Foundation. MASAC Document #151: MASAC recommendations concerning the treatment of hemophilia and other bleeding disorders. 2003.
25. Soldan K, Davison K, Dow B. Estimates of the frequency of HBV, HCV, and HIV infectious donations entering the blood supply in the United Kingdom, 1996 to 2003. Euro Surveill. 2005;10:17-19.
26. Pealer LN, Marfin AA, Petersen LR, et al. Transmission of West Nile virus through blood transfusion in the United States in 2002. N Engl J Med. 2003;349:1236-1245.
27. Peden AH, Head MW, Ritchie DL, et al. Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet. 2004;364:527-529.
28. Dolan G. Clinical implications of emerging pathogens in haemophilia: the variant Creutzfeldt-Jakob disease experience. Haemophilia. 2006;12(Suppl 1):16-20; discussion 26-18.
29. Llewelyn CA, Hewitt PE, Knight RS, et al. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet. 2004;363:417-421.
30. Turner ML, Ludlam CA. An update on the assessment and management of the risk of transmission of variant Creutzfeldt-Jakob disease by blood and plasma products. Br J Haematol. 2009;144:14-23.
31. Abe H, Sugawara H, Hirayama J, et al. Removal of parvovirus B19 from hemoglobin solution by nanofiltration. Artif Cells Blood Substit Immobil Biotechnol. 2000;28:375-383.
32. Chandra S, Groener A, Feldman F. Effectiveness of alternative treatments for reducing potential viral contaminants from plasma-derived products. Thromb Res. 2002;105:391-400.
33. Knight RS, Will RG. Prion diseases. J Neurol Neurosurg Psychiatry. 2004;75 Suppl 1:i36-i42.
34. Eis-Hubinger AM, Sasowski U, Brackmann HH. Parvovirus B19 DNA contamination in coagulation factor VIII products. Thromb Haemost. 1999;81:476-477.
35. Eis-Hubinger AM, Sasowski U, Brackmann HH, et al. Parvovirus B19 DNA is frequently present in recombinant coagulation factor VIII products. Thromb Haemost. 1996;76:1120.
36. Soucie JM, Siwak EB, Hooper WC, et al. Human parvovirus B19 in young male patients with hemophilia A: associations with treatment product exposure and joint range-of-motion limitation. Transfusion. 2004;44:1179-1185.
37. Guidelines on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. Haemophilia. 2003;9:1-23.
38. Association of Hemophilia Clinic Directors of Canada. Clinical Practice Guidelines: Hemophilia and von Willebrand's Disease (2. Management; Update 2); 1999.
39. Centers for Disease Control. Report on the Universal Data Collection Program 2004.
40. Ewenstein BM, Collins P, Tarantino MD, et al. Hemophilia therapy innovation: development of an advanced category recombinant factor VIII by a plasma/albumin-free method. Proceedings of a Special Symposium at the XIXth Congress of the International Society on Thrombosis and Haemostasis, July 12-18, 2003, Birmingham, UK. Semin Hematol. 2004;41:1-16; discussion 16-18.
41. Tarantino MD, Collins PW, Hay CR, et al. Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/ albumin-free method: pharmacokinetics, efficacy, nd safety in previously treated patients with haemophilia A. Haemophilia. 2004;10:428-437.
42. Blanchette VS, Shapiro AD, Liesner RJ, et al. Plasma and albuminfree recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients. J Thromb Haemost. 2008;6:1319-1326.
43. Negrier C, Shapiro A, Berntorp E, et al. Surgical evaluation of a recombinant factor VIII prepared using a plasma/albumin-free method: efficacy and safety of Advate in previously treated patients. Thromb Haemost. 2008;100:217-223.
44. Mantovani LG, Monzini MS, Mannucci PM, et al. Differences between patients', physicians' and pharmacists' preferences for treatment products in haemophilia: a discrete choice experiment. Haemophilia. 2005;11:589-597.
45. White GC 2nd, Courter S, Bray GL, et al. A multicenter study of recombinant factor VIII (Recombinate) in previously treated patients with hemophilia A. The Recombinate Previously Treated Patient Study Group. Thromb Haemost. 1997;77:660-667.
46. Abshire TC, Brackmann HH, Scharrer I, et al. Sucrose formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy-International Kogenate-FS Study Group. Thromb Haemost. 2000;83:811-816.
47. Lusher JM, Lee CA, Kessler CM, et al. The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A, Haemophilia. 2003;9:38-49.
48. Bray GL, Gomperts ED, Courter S, et al. A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group. Blood. 1994;83:2428-2435.
49. Kreuz W, Gill JC, Rothschild C, et al. Full-length sucrose-formulated recombinant factor VIII for treatment of previously untreated or minimally treated young children with severe haemophilia A: results of an international clinical investigation. Thromb Haemost. 2005;93:457-467.
50. Wilson K, Ricketts MN. Transfusion transmission of vCJD: a crisis avoided? Lancet. 2004;364:477-479.
51. White GC 2nd, Rosendaal F, Aledort LM, et al. Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost. 2001;85:560.